Invention Grant
- Patent Title: Mutants of recombinant immunoregulatory protein of
-
Application No.: US16462941Application Date: 2018-03-14
-
Publication No.: US12077566B2Publication Date: 2024-09-03
- Inventor: Fei Sun , Chongyang Liang
- Applicant: Xitian Zhang , Fei Sun , Xin Zhang
- Applicant Address: CN Jilin
- Assignee: Xitian Zhang,Fei Sun,Zin Zhang
- Current Assignee: Xitian Zhang,Fei Sun,Zin Zhang
- Current Assignee Address: CN Jilin; CN Jilin; CN Jilin
- Agency: Merchant & Gould P.C.
- Priority: CN 1710226093.3 2017.04.08
- International Application: PCT/CN2018/078934 2018.03.14
- International Announcement: WO2018/184448A 2018.10.11
- Date entered country: 2019-05-22
- Main IPC: C07K14/375
- IPC: C07K14/375 ; A61K38/00 ; A61K38/17 ; A61P35/00 ; A61P35/04

Abstract:
Mutants of recombinant immunoregulatory protein of Ganoderma lucidum (rLZ-8) and applications thereof are provided. It is found by the present invention that: an anti-EGFR (epidermal growth factor receptor) domain exists in a structure of the rLZ-8; particularly, the domain through positive potential characteristics thereof induces a killing effect to an abnormal EGFR-expressed tumor. Based on the above scientific discovery, with utilizing computational simulation technology, the mutants of the rLZ-8, having better antitumor effects, are obtained.
Public/Granted literature
- US20190352345A1 Mutants of recombinant immunoregulatory protein of Ganoderma lucidum and applications thereof Public/Granted day:2019-11-21
Information query